Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Oncopeptides AB

ONCO.ST ✓ COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Biotechnology & Medical Research ·

Sweden Micro Cap Analyst: HOLD

Last Close

$0.17

▼ -1.39%

Market Cap $77.80M · Vol 6.77M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$77.80M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

+56.46%

YoY

RSI (14)

39.84

Momentum

Beta

0.08

vs Market

52W High

$0.56

70.12% below

52W Low

$0.13

28.23% above

Volume

6.77M

Avg 6.81M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

96.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Oncopeptides AB (ONCO.ST) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ONCO.ST pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.64%

-17.48%

+6.38%

+28.79%

YTD

-62.50%

-64.04%

-59.46%

-44.72%

Financials & Valuation

TTM · Annual

Total Revenue	$7.73M
Net Income	$-27,131,645.00
Revenue Growth (YoY)	+62.12%
Gross Margin	98.94%
Operating Margin	-312.46%
Net Profit Margin	-350.94%
ROE	N/A
ROA · ROIC	-130.76% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	15.34
P/B	N/A
P/FCF	N/A
EPS Growth	+56.46%
Outstanding Shares	431.36M

Technical Indicators

50-Day SMA	$0.20
200-Day SMA	$0.18
RSI (14)	39.84
Beta	0.08
52-Week High	$0.56
52-Week Low	$0.13

Volume Today	6.77M
Avg Daily Volume (30D)	6.81M
Relative Volume	0.99x
Volatility (10D)	27.92
Volatility (30D)	148.15
Free Float	96.60%

Analyst Consensus

HOLD

Current Price $0.17

Mean Target $0.28

52W Low$0.13 52W High$0.56

Current

Target

$0.13 $0.56

Current Analyst target

+62.85% upside potential · 2 analysts

Identifiers

ExchangeEurope

FIGIBBG004LT4BN0

ISINSE0009414576

CountrySweden

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +3.34% ARGX.BR argenx SE +0.07% ARGX argenx SE -3.93% GMAB.CO Genmab A/S +1.59% GMAB Genmab A/S -4.32%

Company Profile

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.